Global Rare Disease Drug Market Size By Therapy Area (Oncology, Hematology), By Drug Type (Biological, Non-biological), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Geographic Scope And Forecast

Rare Disease Drug Market Size And Forecast

Rare Disease Drug Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2022 to 2030.

The increased emphasis on research activities and the development of novel therapeutic drugs has increased the value of the Rare Disease Drug Market. Furthermore, increasing product development is resulting in the use of technologically driven innovative devices in the diagnosis of rare genetic disorders. Furthermore, favorable government policies aimed at raising awareness about rare disease drugs are leading to an increase in the use of effective treatments for rare disorders. The Global Rare Disease Drug Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors playing a substantial role in the market.

Global Rare Disease Drug Market Definition

A rare disease is defined as a disease that affects only a small proportion of the population. In some parts of the world, an orphan disease is a rare disease that lacks a large enough market to gain support and resources for discovering treatments for it, unless the government grants economically advantageous conditions for developing and selling such treatments. Rare Disease drugs are those that have been created or sold for this purpose. Because most rare diseases are genetic, they are present throughout a person’s life, even if symptoms do not appear immediately.

Many rare diseases manifest themselves early in life, and approximately 30% of children with rare diseases die before reaching the age of five. Ribose-5-phosphate isomerase deficiency is the rarest genetic condition known, with only four people diagnosed in 27 years. There is no single cut-off number for determining whether a disease is rare. A disease may be rare in one part of the world or among one group of people, but common in another.

Rare diseases do not have a single, widely accepted definition. Some definitions are based solely on the number of people living with a disease, while others include additional factors such as the availability of adequate treatments or the severity of the disease. The Rare Diseases Act of 2002 in the United States defines rare diseases strictly according to prevalence, specifically “any disease or condition that affects fewer than 200,000 people in the United States,” or approximately one in every 1,500 people. This definition is nearly identical to that of the Orphan Drug Act of 1983, a federal law enacted to encourage research into rare diseases and potential cures.

The legal definition of a rare disease in Japan affects fewer than 50,000 patients or about one in every 2,500 people. are diseases, on the other hand, are defined by the European Commission on Public Health as “life-threatening or chronically debilitating disorders of such low prevalence that extraordinary coordinated efforts are necessary to address them”. The term “low prevalence” is later defined as fewer than one in every 2,000 people. Diseases that are statistically rare but not also life-threatening, chronically debilitating, or inadequately treated are excluded. The definitions used in the medical literature and by national health plans are similarly divided, ranging from 1/1,000 to 1/200,000.

Global Rare Disease Drug Market Overview

The growth drivers for the market are an increase in the number of rare disease cases across the globe, Favorable government policies, a Growing number of new drug launches, and Increasing R&D activities for novel therapeutics and drugs. The rise in the number of rare diseases will fuel the expansion of the Rare Disease Drug Market. According to a Journal of Rare Disorders (2020) article, there are approximately 7,000 classified rare disorders, with approximately 70% of these disorders having no treatment. As a result, ongoing research for unmet rare disease treatments will result in several market expansion opportunities in the future. Furthermore, according to the Global Genes Project, rare diseases affect approximately 300 million people worldwide.

Because of the high prevalence of people suffering from rare disorders, special drugs will be required, accelerating the adoption of rare disease drugs. To drive global market growth, R&D initiatives are being expanded. Increased R&D investments by prominent players for rare disease drug development of novel product offerings is one of the critical driving factors prevailing in the global market. Since the public’s awareness and understanding of rare diseases have grown, several key clinical-stage biopharmaceutical companies and established market players have a strong pipeline of rare disease drugs in various stages of clinical trials.

This growing interest in rare disorder therapeutics is because major pharmaceutical breakthroughs resulting in blockbuster drug developments are more likely in rare disorders than in traditional pharmaceutical portfolios. The restraints for the market growth are a Lack of awareness regarding rare disease treatment and the High Cost of the drugs and therapy. Whereas the is growth potential in untapped emerging nations and growth in novel indications for known rare disease drugs.

Global Rare Disease Drug Market Segmentation Analysis

The Global Rare Disease Drug Market is segmented on the basis of Therapy Area, Drug Type, Distribution Channel, And Geography.

Rare Disease Drug Market, By Therapy Area

• Oncology• Hematology• Neurology• Cardiovascular• Other Disease Types

Based on Therapy Area, the market is segmented into Oncology, Hematology, Neurology, Cardiovascular, and Other Disease Types. In terms of market share for rare disease drugs, the oncology segment is dominant. The dominance is due to the presence of several oncology drugs in key players’ product development pipelines, as well as the presence of a large number of Rare Disease drugs dedicated to cancer treatment. Due to several new product launches and increasing positive regulatory approvals, the hematology segment is expected to be the second most dominant segment. The neurology segment is also expected to grow at a relatively fast rate due to improvements in product offerings for key diseases such as multiple sclerosis.

Rare Disease Drug Market, By Drug Type

• Biological• Non-biological

Based on Drug Type, the market is bifurcated into Biological and Non-biological. The overwhelming presence of biologic product offerings is one of the major factors responsible for the segment’s dominance. According to the United States Food and Drug Administration (U.S. FDA), the organization’s Orphan Products Development (OOPD) program has resulted in the development and marketing of over 600 drugs and biologic products for rare disorders since 1983. The non-biologics segment accounted for a smaller share of the global market and had a lower CAGR.

Rare Disease Drug Market, By Distribution Channel

• Hospital Pharmacy• Retail Pharmacy• Online Pharmacy• Others

Based on Distribution Channel, the market is bifurcated into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others. During the forecast period, hospital pharmacies are expected to have the largest market share. The primary reason for this dominance is that a significant number of drugs must be administered intravenously by trained healthcare professionals in hospitals.

Rare Disease Drug Market, By Geography

• North America• Europe• Asia Pacific• Rest of the world

On the basis of Geography, the Global Rare Disease Drug Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America currently dominates the Rare Disease Drug Market and is expected to do so for the foreseeable future. The United States has the largest market share in North America. One reason for market growth is that in the United States, a drug designated as a Rare Disease drug receives seven years of marketing exclusivity upon FDA approval for a specific indication, as well as tax credits and a user fee waiver.

Key Players

The “Global Rare Disease Drug Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Novartis AG, F Hoffmann-La Roche Ltd., Celgene Corporation, Bristol-Myers Squibb Company, Shire plc, Pfizer, Inc., Sanofi S.A., Bayer, Alexion Pharmaceuticals, Inc., Biogen, Inc., Abbvie Inc., Amgen Inc., Amryt Pharma Plc., GlaxoSmithKline Plc (Gsk), Johnson & Johnson (Janssen Global Services, Llc). The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In May 2020, AstraZeneca and Daiichi Sankyo Company announced that Enhertu (trastuzumab deruxtecan) received FDA Orphan Drug Designation for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

• In June 2020, Agios Pharmaceuticals, Inc. announced that their pipeline candidate Mitapivat for the treatment of Thalassemia had received FDA Orphan Drug Designation.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.